Binding kinetics and mechanism of action: Toward the discovery and development of better and best in class drugs

Expert Opinion on Drug Discovery

Volumn 5, Issue 11, 2010, Pages 1023-1029

  Zhang, Rumin ^a   Monsma, Frederick ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

best in class drugs; BK; drug discovery and development; drugtarget residence time; MOA; proof of concept

Indexed keywords

BINDING AFFINITY; BINDING KINETICS; DISSOCIATION CONSTANT; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENERGY TRANSFER; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; STOICHIOMETRY; VALIDATION PROCESS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; KINETICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 77958535230     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.520700     Document Type: Review

References (37)

1. Zhang R, Monsma F. The importance of drug-target residence time. Curr Opin Drug Discov Devel 2009;12(4):488-96
2. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5(9):730-9
3. Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008;47(20):5481-92
4. Copeland RA. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin Drug Discov 2010;5(4):305-10
5. Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 2009;12(1):31-9
6. Vauquelin G. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin Drug Discov 2010; In press
7. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004;3(9):801-8
8. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001;15(3):598-611
9. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 2007;72(6):1393-401
10. Goyal M, Rizzo M, Schumacher F, et al. Beyond thermodynamics: drug binding kinetics could influence epidermal growth factor signaling. J Med Chem 2009;52(18):5582-5
11. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009;25(19):2466-72
12. Rajasethupathy P, Vayttaden SJ, Bhalla US. Systems modeling: a pathway to drug discovery. Curr Opin Chem Biol 2005;9(4):400-6
13. Haugh JM, Wells A, Lauffenburger DA. Mathematical modeling of epidermal growth factor receptor signaling through the phospholipase C pathway: mechanistic insights and predictions for molecular interventions. Biotechnol Bioeng 2000;70(2):225-38
14. Sung MH, Simon R. In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics. Mol Pharmacol 2004;66(1):70-5
15. Christopher R, Dhiman A, Fox J, et al. Data-driven computer simulation of human cancer cell. Ann NY Acad Sci 2004;1020:132-53
16. Cooper MA. Signal transduction profiling using label-free biosensors. J Recept Signal Transduct Res 2009;29(3-4):224-33
17. Rich RL, Papalia GA, Flynn PJ, et al. A global benchmark study using affinity-based biosensors. Anal Biochem 2009;386(2):194-216
18. Berezhkovskiy LM. The analysis of peptide affinity and its binding kinetics to DR1DW1 major histocompatibility complex protein. Biophys Chem 1999;77(2-3):183-94
19. Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 1984;25(1):1-9
20. Copeland RA. Enzymes: a practical introduction to structure, mechanism and data analysis. Wiley, New York; 2000
21. Copeland RA. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley, Hoboken, NJ; 2005
22. Zhang R, Monsma F. Fluorescence-based thermal shift assays. Curr Opin Drug Discov Devel 2010;13(4):389-402
23. Kenakin TP. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov 2009;8(8):617-26
24. Kenakin TP. Ligand detection in the allosteric world. J Biomol Screen 2010;15(2):119-30
25. Grime KH, Bird J, Ferguson D, et al. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 2009;36(2-3):175-91
26. Perloff ES, Mason AK, Dehal SS, et al. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 2009;39(2):99-112
27. Sekiguchi N, Higashida A, Kato M, et al. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 2009;24(6):500-10
28. Peletier LA, Benson N, van der Graaf PH. Impact of plasma-protein binding on receptor occupancy: an analytical description. J Theor Biol 2009;256(2):253-62
29. Trainor GL. The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov 2007;2(1):51-64
30. Berezhkovskiy LM. Some features of the kinetics and equilibrium of drug binding to plasma proteins. Expert Opin Drug Metab Toxicol 2008;4(12):1479-98
31. Gabrielsson J, Dolgos H, Gillberg PG, et al. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today 2009;14(7-8):358-72
32. Grimwood S, Hartig PR. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther 2009;122(3):281-301
33. Westley AM, Westley J. Enzyme inhibition in open systems. Superiority of uncompetitive agents. J Biol Chem 1996;271(10):5347-52
34. Swinney DC. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 2006;6(5):461-78
35. Ladbury JE, Klebe G, Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov 2010;9(1):23-7
36. Mendes P, Hoops S, Sahle S, et al. Computational modeling of biochemical networks using COPASI. Methods Mol Biol 2009;500:17-59
37. Hoops S, Sahle S, Gauges R, et al. COPASI - a COmplex PAthway SImulator. Bioinformatics 2006;22(24):3067-74